Publicaciones en colaboración con investigadores/as de Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (111)

2024

  1. Angiotensin type 1 receptor activation promotes neuronal and glial alpha-synuclein aggregation and transmission

    npj Parkinson's Disease, Vol. 10, Núm. 1

  2. Ionizable nanoemulsions for RNA delivery into the central nervous system – importance of diffusivity

    Journal of Controlled Release, Vol. 372, pp. 295-303

  3. Levodopa-Induced Dyskinesias are Frequent and Impact Quality of Life in Parkinson's Disease: A 5-Year Follow-Up Study

    Movement Disorders Clinical Practice, Vol. 11, Núm. 7, pp. 830-849

  4. Non-HLA angiotensin-type-1 receptor autoantibodies mediate the long-term loss of grafted neurons in Parkinson’s disease models

    Stem Cell Research and Therapy, Vol. 15, Núm. 1

  5. Novel risk loci for COVID-19 hospitalization among admixed American populations

    eLife, Vol. 13

  6. The role of the brain renin-angiotensin system in Parkinson´s disease

    Translational Neurodegeneration, Vol. 13, Núm. 1

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. AT1 receptor autoantibodies mediate effects of metabolic syndrome on dopaminergic vulnerability

    Brain, Behavior, and Immunity, Vol. 108, pp. 255-268

  3. Boolean analysis shows a high proportion of dopamine D2 receptors interacting with adenosine A2A receptors in striatal medium spiny neurons of mouse and non-human primate models of Parkinson's disease

    Neurobiology of Disease, Vol. 188

  4. Depression in Major Neurodegenerative Diseases and Strokes: A Critical Review of Similarities and Differences among Neurological Disorders

    Brain Sciences, Vol. 13, Núm. 2

  5. Depressive Symptoms and Their Impact on Quality of Life in Parkinson’s Disease: An Exploratory Network Analysis Approach

    Journal of Clinical Medicine, Vol. 12, Núm. 14

  6. Expanded and Independent Spanish Validation of the MDS-Non Motor Rating Scale

    Movement Disorders Clinical Practice, Vol. 10, Núm. 4, pp. 586-595

  7. Extracellular Vesicles and Their Renin–Angiotensin Cargo as a Link between Metabolic Syndrome and Parkinson’s Disease

    Antioxidants, Vol. 12, Núm. 12

  8. Interactions between Angiotensin Type-1 Antagonists, Statins, and ROCK Inhibitors in a Rat Model of L-DOPA-Induced Dyskinesia

    Antioxidants, Vol. 12, Núm. 7

  9. Neuromelanin accumulation drives endogenous synucleinopathy in non-human primates

    Brain : a journal of neurology, Vol. 146, Núm. 12, pp. 5000-5014

  10. Prevalence and Factors Associated with Drooling in Parkinson's Disease: Results from a Longitudinal Prospective Cohort and Comparison with a Control Group

    Parkinson's Disease, Vol. 2023

  11. Risk of Cognitive Impairment in Patients With Parkinson’s Disease With Visual Hallucinations and Subjective Cognitive Complaints

    Journal of Clinical Neurology (Korea), Vol. 19, Núm. 4, pp. 344-357

  12. Sex Differences in Motor and Non-Motor Symptoms among Spanish Patients with Parkinson’s Disease

    Journal of Clinical Medicine, Vol. 12, Núm. 4

  13. Staging Parkinson's Disease According to the MNCD (Motor/Non-motor/Cognition/Dependency) Classification Correlates with Disease Severity and Quality of Life

    Journal of Parkinson's disease, Vol. 13, Núm. 3, pp. 379-402

  14. Staging Parkinson's disease according to the MNCD classification correlates with caregiver burden

    Brain and Behavior, Vol. 13, Núm. 12